skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: THE USE OF POSITRON EMITTING ISOTOPES IN THE LOCALIZATION OF INTRACRANIAL LESIONS. Period covered: May 15, 1961-February 14, 1962

Technical Report ·
OSTI ID:4811591

The results of clinical data on the intra-arterial injection technique include scanning tumor depictions from 19 patients who had both intravenous and intracarotid injections of positron-emitting As/sup 74/ arsenate. The findings indicated that fractional intra-arterial injections may be used to significantly lower the patient dosage and to increase the legibility of tumor images. The technique was of real value only for patients harboring intrinsic tumors. However, fractional injections did not fail diagnostically when administered inadvertently to patients with meningiomas because of the avid isotopic uptake by these tumors. It was also found that the dosage for routine intravenous injection (in tumor suspects without indication for early angiography) could be satisfactorily reduced to 750 mu c. As/sup 74/ sodium arsenate, As/sup 74/ arsanilic acid, and As/sup 74/ azoproteins were injected into tumor-bearing mice for evaluation as possible tumor-localizing agents. Tumor to brain ratios for As/sup 74/ arsenate were about 8: 1 and for As/sup 74/ arsanilate about 16: 1 (1 hr. after injection). The uptake of As/sup 74/ arsanilate was about one-third less than that of As/sup 74/ arsenate. The enhanced tumor to brain ratios obtained with arsanilate appeared to be due to a decreased uptake in brain tissue. The As/sup 74/ azproteins contained either 8, 5, or 1-2 molecules of As/sup 74/ arsanilate per molecule of protein. Preliminary results indicated that more extensive labeling results in more rapid disappearance from the blood stream, greater accumulation in kidney and liver, and less uptake in tumor. Tumor to brain ratios obtained with the less extensively labeled material averaged about 20 to 40: 1 and were maintained for at least 48 hr. (auth)

Research Organization:
Baltimore. City Hospitals
DOE Contract Number:
AT(30-1)-2182
NSA Number:
NSA-16-009744
OSTI ID:
4811591
Report Number(s):
TID-14952
Resource Relation:
Other Information: Orig. Receipt Date: 31-DEC-62
Country of Publication:
United States
Language:
English